
Repligen (RGEN) Stock Forecast & Price Target
Repligen (RGEN) Analyst Ratings
Bulls say
Repligen has raised its full-year 2025 revenue guidance to a range of $715-735 million, compared to the previous guidance of $695-720 million, indicating positive momentum in its financial performance. The company experienced a significant year-over-year growth in its CDMO segment and a robust 20% increase in biopharma revenue, showcasing strong demand across its customer base. Additionally, consumables sales surged by over 20%, complemented by a high-teens growth rate in capital equipment, further strengthening the outlook for continued revenue expansion.
Bears say
Repligen faces multiple inherent risks that contribute to a negative outlook on its stock, including the potential failure to successfully develop and launch new products, which could impede revenue growth. Additionally, the company's ability to close new mergers and acquisitions is crucial for expansion, and any shortcomings in this area may impact market position negatively. Furthermore, challenges related to market penetration and increasing competition, coupled with potential dilution risks, could adversely affect future profitability and shareholder value.
This aggregate rating is based on analysts' research of Repligen and is not a guaranteed prediction by Public.com or investment advice.
Repligen (RGEN) Analyst Forecast & Price Prediction
Start investing in Repligen (RGEN)
Order type
Buy in
Order amount
Est. shares
0 shares